Asymptomatic primary hyperparathyroidism: Management and implications

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 4, Issue 2, 2010, Pages 138-145

  Trofimiuk, Malgorzata ^a   Pach, Dorota ^a   Hubalewska Dydejczyk, Alicja ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Antiresorptive therapies; Asymptomatic hyperparathyroidism; Calcimimetics; Normocalcemic hyperparathyroidism; Parathyroidectomy; Primary hyperparathyroidism; Vitamin D

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCIUM; PARATHYROID HORMONE; VITAMIN D;

ARTICLE; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; ENDOCRINE SURGERY; FOLLOW UP; MINIMALLY INVASIVE PROCEDURE; OSTEOPOROSIS; PRACTICE GUIDELINE; PREVALENCE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RISK FACTOR;

EID: 77953764134     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221410791196579     Document Type: Article

References (90)

1. Khan AA, Bilezikian JP, Potts JT Jr. The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. J Clin Endocrinol Metab 2009; 94: 333-34.
2. Wermers RA, Khosla S, Atkinson EJ, Oberg AL, Grant CS, Melton LJ III. Incidence of primary hyperparathyroidism in rochester, minnesota, 1993-2001: An Update on the Changing Epidemiology of the disease. J Bone Miner Res 2006; 21: 171-7.
3. Jorde R, Bonaa KH, Sundsfjord J. Primary hyperparathyroidism detected in a health screening: The Tromso Study. J Clin Epidemiol 2000; 53: 1164-9.
4. Richert L, Trombetti A, Herrmann FR, Triponez F, Meier C, Robert JH, et al. Age and gender distribution of primary hyperparathyroidism and incidence of surgical treatment in a European country with a particularly high life expectancy. Swiss Med Wkly 2009; 139: 400-4.
5. Kirdak T, Quan-Yang D, Kebebew E, Clark OH. Do patients undergoing parathyroidectomy for primary hyperparathyroidism in San Francisco, CA, and Bursa, Turkey, differ? Am J Surg 2009; 198: 188-92.
6. Oliveira UEM, Ohe MN, Santos RO, Cervantes O, Abrahao M, Lazaretti-Castro M, et al. Analysis of the diagnostic presentation profile, parathyroidectomy indication and bone mineral density follow-up of Brazilian patients with primary hyperparathyroidism. Braz J Med Biol Res 2007; 40: 519-26.
7. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008; 93: 3462-70.
8. Scholz DA, Purnell DC. Asymptomatic primary hyperparathyroidism. 10-year prospective study. Mayo Clin Proc 1981; 56: 473-8.
9. Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: Evidence for biphasic disease course. J Clin Endocrinol Metab 1988; 67: 1294-8.
10. Lundgren E, Szabo E, Ljunghall S, Bergstrom R, Holmberg L, Rastad J. Population based case-control study of sick leave in postmenopausal women before diagnosis of hyperparathyroidism. BJM 1998; 317: 848-51.
11. Nilsson IL, Yin L, Lundgren E, Rastad J, Ekbom A. Clinical presentation of primary hyperparathyroidism in Europe-nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res 2002; 17 (Suppl 2): N68-N74.
12. Wermers RA, Khosla S, Atkinson EJ, Grant CS, Hodgson SF, O'Fallon WM, et al. Survival after the diagnosis of hyperparathyroidism: A population-based study. Am J Med 1998; 104: 115-22.
13. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: Proceedings of the Third International Workshop. J Clin Endocrinol Metab 2009; 94: 351-65.
14. Rubin MJ, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ. Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90: 3326-30.
15. Barletta G, DeFeo ML, Del Bene R, Lazzeri C, Vecchiarino S, La Villa G, et al. Cardiovascular effects of parathyroid hormone: A study in healthy subjects and normotensive patients with mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000; 85: 1815-21.
16. Procopio M, Magro G, Cesario F, Piovesan A, Pia A, Molineri N, et al. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed type 2 diabetes mellitus in primary hyperparathyroidism. Diabet Med 2002; 19: 958-61.
17. Lungren E, Ljunghall S, Akerstrom G, Hetta J, Mallmin H, Rastad J. Case-control study on symptoms and signs of asymptomatic primary hyperparathyroidism. Surgery 1998; 124: 980-6.
18. Ayturk S, Gursoy A, Tutuncu NB, Ertugrul DT, Demirag NG. Changes in insulin sensitivity and glucose and bone metabolism over time in patients with asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2006; 91: 4260-3.
19. Khosla S, Metlon III LJ, Wermers RA, Crowson CA, O'Fallon WM, Riggs BL. Primary hyperparathyroidism and the risk of fracture: A population-based study. J Bone Miner Res 1999; 14: 1700-07.
20. Roschger P, Dempster DW, Zhou H, Paschalis EP, Silverberg SJ, Shane E, et al. New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscaterred electron imaging. J Bone Miner Res 2007; 22: 717-23.
21. Amborginini E, Cetani F, Cianeferotti L, Vignali E, Banti C, Viccica G, et al. Surgery vs surveillance for mild asymptomatic primary hyperparathyroidism: A prospective, randomized clinical trial. J Clin Endocrinol Metab 2007; 92: 3114-21.
22. Bollerslev J, Jansson S, Mollerup CL, Nordenström J, Lundgren E, Tørring O, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: A prospective, randomized trial. J Clin Endocrinol Metab 2007; 92: 1687-92.
23. Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2004; 89: 5415-22.
24. Talpos GB, Bone HG, Kleerekorper M, Phillips ER, Alam M, Honasoge M, et al. Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: Patient description and effects of the SF-36 health survey. Surgery 2000; 128: 1013-21.
25. Walker MD, McMahon DJ, Inabnet WB, Lazar RM, Brown I, Vardy S, et al. Neuropsychological features in primary hyperparathyroidism. J Clin Endocrinol Metab 2009; 94: 1951-58.
26. Eastell R, Arnold A, Brandi ML, Brown EM, D'Amour P, Hanley DA, et al. Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the Third International Workshop. J Clin Endocrinol Metab 2009; 94: 340-50.
27. Leparge R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, et al. A non-(1-84) circulating parathyroid hormone (PTH) fragments interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998; 44: 805-9.
28. John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Jüppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: Implications for PTH measurements in renal failure. J Clin Endocrinol Metabol 1999; 84: 4287-90.
29. Sourbielle JC, Boudou P, Cormier C. Lessons from second and third-generation parathyroid hormone assays in primary hyperparathyroidism. J Endocrinol Invest 2008; 31: 463-9.
30. Bandeira F, Griz LH, Bandeira C, Pinho J, Lucena C, Alencar C, et al. Prevalence of cortical osteoporosis in mild and severe primary hyperparathyroidism and its relationship with bone markers and Vitamin D status. J Clin Densitom 2009; 12: 195-99.
31. Silverberg SJ. Vitamin D deficiency in primary hyperparathyroidism. J Bone Miner Res 2007; 22(S2): V100-V104.
32. Bishop, C. W., Crawford, K. H., Messener, E. J., Petkovich, M. P., Helvig, C. F. Method of treating and preventing secondary hyperparathyroidism. US2009209501 (2009).
33. Rao DS, Honasoge M, Divine GW, Phillips ER, Lee MW, Ansari MR, et al. Effect of Vitamin D nutrition on parathyroid adenoma weight: Pathogenic and clinical implications. J Clin Endocrinol Metab 2000; 85: 1054-8.
34. Moosgaard B, Vestergaard P, Heickendorfft L, Melsen F, Christiansen P, Mosekilde L, et al. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone density in primary hyperparathyroidism. Clin Endocrinol (Oxf) 2005; 63: 506-13.
35. Silverberg SJ, Shane E, Dempster DW, Bilezikian JP. The effects of Vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med 1999; 107: 561-67.
36. Beyer TD, Chen EL, Nilubol N, Prinz RA, Solozarno CS. Shortterm outcomes of parathyroidectomy in patients with or without 25-hydroxy Vitamin D insufficiency. J Surg Res 2007; 143: 145-10.
37. Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR. Vitamin D repletion in patient with primary hyperparathyroidism and coexistent Vitamin D insufficiency. J Clin Endocrinol Metab 2005; 90: 2122-6.
38. Isidro ML, Ruano B. Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant Vitamin D deficiency. Endocrinology 2009; 36: 305-10.
39. Silverberg SJ, Bilezikian JP. "Incipient" primary hyperparathyroidism: A "forme fruste" of an old disease. J Clin Endocrinol Metab 2003; 88: 5348-2.
40. Lundgren E, Rastard J, Thrufjell E, Akerstrom G, Ljunghall S. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 1997; 121: 287-94.
41. Lowe H, McMahon J, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: Further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007; 92: 3001-5.
42. Hagstrom E, Lundgren E, Rastard J, Hellman P. Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur J Endocrinol 2006; 155: 33-39.
43. Maruani G, Hertig A, Paillard M, Houillier P. Normocalcemic primary hyperparathyroidism: Evidence for a generalized targettissue resistance to parathyroid hormone. J Clin Endocrinol Metab 2003; 88: 4641-8.
44. Hagag P, Revet-Zak I, Hod N, Horne T, Rapoport MJ, Weiss M. Diagnosis of normocalcemic hyperparathyrodidsm by oral calcium loading test. J Endocrinol Invest 2003; 26: 327-32.
45. Nakchbandi IA, Lang R, Kinder B, Insogna KL. The role of the receptor activator of nuclear factor-kappa B ligand/osteoprotegerin cytokine system in primary hyperparathyroidism. J Clin Endocrinol Metab 2008; 93: 967-73.
46. Abbas JS, Hashem SI, Faraj WG, Khalifeh MJ, Horani MH, Salti IS. The outcome of cervical exploration for asymptomatic and symptomatic patients with primary hyperparathyroidism. World J Surg 2006; 30: 69-75.
47. 99mTc-Sestamibi scanning between severe and mild forms of primary hyperparathyroidism. J Nucl Med Technol 2008; 36: 30-35.
48. Delbridge LW, Younes NA, Guinea AI, Reeve TS, Clifton-Blight P, Robinson BG. Surgery for primary hyperparathyroidism 1962-1996: Indications and outcomes. MJA 1998; 168: 153-56.
49. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Eng J Med 1999; 341: 1249-5.
50. Tsukahara K, Sugitani I, Fujimoto Y, Kwabata K. Surgery did not improve the subjective neuropsychological symptoms of patients with incidentally detected mild primary hyperparathyroidism. Eur Arch Otorhinolaryngol 2008; 265: 565-69.
51. Hagstrom E, Lundgren E, Mallmin H, Rastad J, Hellman P. Positive effect of parathyroidectomy on bone mineral density in mild asymptomatic primary hyperparathyroidism. J Int Med 2006; 259: 191-98.
52. Hagstrom E, Lundgren E, Lithell H, Berglund L, Ljunghall S, Hellman P, et al. Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: Population based study over five years. Clin Endocrinol (Oxf) 2002; 56: 253-60.
53. Bilezikian JP, Khan AA, Potts JT. Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the Third International Workshop. J Clin Endocrinol Metab 2009; 94: 335-9.
54. Sejean K, Calmus S, Durand-Zaleski I, Bonnichon P, Thomopoulos P, Cormier C, et al. Surgery versus medical follow-up in patients with asymptomatic primary hyperparathyroidism: A decision analysis. Eur J Endocrinol 2005; 153: 915-27.
55. Inabnet WB, Fulla Y, Richard B, Bonnichon P, Icard P, Chapuis Y. Unilateral neck exploration under local anesthesia: The approach of choice for asymptomatic primary hyperparathyroidism. Surgery 1999; 126: 1004-10.
56. Zanocco K, Angelos P, Stugeon C. Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery 2006; 140: 874-82.
57. Stratigis S, Stylianou K, Mamalaki E, Perakis K, Vardaki E, Tzenakis N, et al. Percutaneous ethanol injection therapy: A surgery-sparing treatment for primary hyperparathyroidism. Clin Endocrinol (Oxf) 2008; 69: 542-58.
58. Karstrup S, Holm HH, Glenthoj A, Hedegus L. Nonsurgical treatment of primary hyperparathyroidism with sonographically guided percutaneous injection of ethanol: Results in a selected series of patients. AJR 1990; 154: 1087-90.
59. Verges BL, Cercueil JP, Jacob D, Vaillant G, Brun JM, Putelat R. Results of ultrasonically guided percutaneous ethanol injection into parathyroid adenomas in primary hyperparathyroidism. Acta Endocrinol (Copenh) 1993; 129: 381-7.
60. Bennedbaek FN, Karstrup S, Hegedus L. Ultrasound guided laser ablation of a parathyroid adenoma. Br J Radiol 2001; 74: 905-7.
61. Pollard RE, Long CD, Nelson RW, Hornof WJ, Feldman EC. Percutanous ultrasonographically guided radiofrequency heat ablation for treatment of primary hyperparathyroidism in dogs. J Am Vet med Assoc 2001; 218: 1106-10.
62. Jorde R, Szumlas K, Haug E, Sundsfjord J. The effect of calcium supplementation to patients with primary hyperparathyroidism and a low calcium intake. Eur J Nutr 2002; 41: 258-63.
63. Mazess, R.B., Strugnell, S.A., Knutson, J.C. Method for treating and preventing hyperparathyroidism. US2009137536 (2009).
64. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med 1996; 125: 360-68.
65. Orr-Walker BJ, Evans MC, Clearwater JM, Horne A, Grey AB, Reid IR. Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism. Arch Intern Med 2000: 160: 2161-6.
66. Zanchetta JR, Bogado CE. Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. J Bone Miner Res, 2001; 16: 189-90.
67. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88: 1174-8.
68. Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S. Effects of oral alendronate In elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 2001; 16: 113-19.
69. Chow CC, Chan WB, Li JKY, Chan NN, Chan MH, Ko GT, et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88: 581-7.
70. Parker CR, Blackwell PJ, Fairbairn KJ, Hosking DJ. Alendronate in the treatment of primary hyperparathyroidism related osteoporosis: A 2-year study. J Clin Endocrinol Metab 2002; 87: 4482-9.
71. Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, et al. Alendronate in primary hyperparathyroidism: A doubleblind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89: 3319-25.
72. Jensen AA, Brauner-Osborne H. Allosteric modulation of the caclium-sensing receptor. Curr Neuropharmacol 2007; 5: 180-6.
73. Corbetta S, Mantovani G, Lania A, Borgato S, Vicentini L, Beretta E, et al. Calcium-sensing receptor expression and signaling in human parathyroid adenomas and primary hyperplasia. Clin Endocrinol (Oxf) 2000; 52: 339-48.
74. Silverberg AJ, Bone III HG, Marriott TB, Locker FG, Thys-Jacobs S, Dziem G, et al. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Eng J Med 1997; 337: 1506-10.
75. Peacock M, Bilezikiam JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90: 135-41.
76. Peacock MP, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 2009; 94: 4860-7.
77. Sajid-crocket S, Singer FR, Hershman JM. Cinacalcet for the treatment of the primary hyperparathyroidism. Metabolism 2008; 57: 517-21.
78. Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab 2009; 94: 2766-72.
79. 2+ receptor. J Biol Chem 2002; 277: 18908-13.
80. Bell, G., Walter, S., Karim, F. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders. WO2008067199 (2009).
81. Hasse C, Zielke A, Burns C, Kunneke M, Ehlenz K, Bachem MG, et al. Influence of somatostatin to biochemical parameters in patients with primary hyperparathyroidism. Exp Clin Endocrinol Diabetes 1995; 103: 391-7.
82. Zielke A, Hasse C, Bruns C, Sitter H, Rothmund M. Octreotide: Effective treatment for hyperparathyroidism? A prospective, randomized, controlled clinical trial. Surgery 1997; 121: 606-10.
83. Lucarotti ME, Hamilton JA, Farndon JR. Somatostatin and primary hyperparathyroidism. Br J Surg 1994; 81: 1141-3.
84. Faggiano A, Tavares LB, Tauchmanova L, Milone F, Mansueto G, Ramundo V, et al. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHT) in multiple endocrine neoplasia type1 (MEN1) patients. Clin Endocrinol (Oxf) 2008; 69: 756-62.
85. Rosen HN, Lim M, Garber J, Moreau S, Bhargava HN, Pallotta J, et al. The effect of PTH antagonist BIM-44002 on serum calcium and PTH levels in hypercalcemic hyperparathyroid patients. Calcif Tissue Int 1997; 61: 455-9.
86. Hofbauer LC, Kuhne CA, Viereck V. The OPG/RANKL/RANK system in metabolic bone disease. J Musculoscel Neuron Interact 2004; 4: 268-75.
87. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354: 821-31.
88. Cummings SR, San Martin J, McClung, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-65.
89. Udelsman R, Pasieka JL, Sturgeon C, Young JEM, Clark OH. Surgery for asymptomatic hyperparathyroidism: Proceedings of the Third International Workshop. J Clin Endocrinol Metab 2009; 94: 366-72.
90. Khan A, Grey A, Shoback D. Medical management of asymptomatic primary hyperparathyroidism: Proceedings of the Third International Workshop. J Clin Endocrinol Metab 2009; 94: 373-81.